S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
Log in

NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price, Forecast & News

$55.81
+0.69 (+1.25 %)
(As of 02/20/2020 04:00 PM ET)
Today's Range
$55.02
Now: $55.81
$56.25
50-Day Range
$54.87
MA: $63.25
$69.40
52-Week Range
$19.88
Now: $55.81
$71.11
Volume421,793 shs
Average Volume561,991 shs
Market Capitalization$2.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.04
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DCPH
CUSIPN/A
Phone781-209-6400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$7.43 per share

Profitability

Net Income$-99,850,000.00

Miscellaneous

Employees112
Market Cap$2.85 billion
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive DCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.


Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) issued its quarterly earnings results on Monday, November, 4th. The company reported ($1.28) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.09. View Deciphera Pharmaceuticals' Earnings History.

When is Deciphera Pharmaceuticals' next earnings date?

Deciphera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Deciphera Pharmaceuticals.

What price target have analysts set for DCPH?

13 brokers have issued 12 month target prices for Deciphera Pharmaceuticals' shares. Their forecasts range from $29.00 to $84.00. On average, they expect Deciphera Pharmaceuticals' stock price to reach $62.23 in the next year. This suggests a possible upside of 11.5% from the stock's current price. View Analyst Price Targets for Deciphera Pharmaceuticals.

What is the consensus analysts' recommendation for Deciphera Pharmaceuticals?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Deciphera Pharmaceuticals.

Has Deciphera Pharmaceuticals been receiving favorable news coverage?

Media stories about DCPH stock have been trending negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Deciphera Pharmaceuticals earned a coverage optimism score of -2.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Deciphera Pharmaceuticals.

Are investors shorting Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,640,000 shares, an increase of 5.6% from the January 15th total of 2,500,000 shares. Based on an average daily volume of 586,200 shares, the short-interest ratio is currently 4.5 days. Currently, 8.5% of the company's stock are short sold. View Deciphera Pharmaceuticals' Current Options Chain.

Who are some of Deciphera Pharmaceuticals' key competitors?

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Who are Deciphera Pharmaceuticals' key executives?

Deciphera Pharmaceuticals' management team includes the folowing people:
  • Dr. Daniel L. Flynn, Exec. VP, Chief Scientific Officer & Founder (Age 64)
  • Mr. Christopher J. Morl, Chief Bus. Officer (Age 60)
  • Countess Steven L. Hoerter, Pres, CEO & Director (Age 48)
  • Mr. Thomas Patrick Kelly J.D., Exec. VP, CFO & Treasurer (Age 48)
  • Dr. Stephen B. Ruddy Ph.D., Chief Technical Officer (Age 55)

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (4.65%), New Leaf Venture Partners L.L.C. (4.09%), ArrowMark Colorado Holdings LLC (3.32%), Alliancebernstein L.P. (2.46%), State Street Corp (2.03%) and Farallon Capital Management LLC (1.86%). Company insiders that own Deciphera Pharmaceuticals stock include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen and Thomas Patrick Kelly. View Institutional Ownership Trends for Deciphera Pharmaceuticals.

Which institutional investors are selling Deciphera Pharmaceuticals stock?

DCPH stock was sold by a variety of institutional investors in the last quarter, including New Leaf Venture Partners L.L.C., Point72 Asset Management L.P., Janus Henderson Group PLC, Alliancebernstein L.P., ArrowMark Colorado Holdings LLC, Kornitzer Capital Management Inc. KS, UBS Group AG and Spark Investment Management LLC. Company insiders that have sold Deciphera Pharmaceuticals company stock in the last year include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen and Thomas Patrick Kelly. View Insider Buying and Selling for Deciphera Pharmaceuticals.

Which institutional investors are buying Deciphera Pharmaceuticals stock?

DCPH stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FMR LLC, State Street Corp, Lord Abbett & CO. LLC, Capital World Investors, Farallon Capital Management LLC, Casdin Capital LLC and Pictet Asset Management Ltd.. View Insider Buying and Selling for Deciphera Pharmaceuticals.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $55.81.

How big of a company is Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals has a market capitalization of $2.85 billion. The company earns $-99,850,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe.View Additional Information About Deciphera Pharmaceuticals.

What is Deciphera Pharmaceuticals' official website?

The official website for Deciphera Pharmaceuticals is http://www.deciphera.com/.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]


MarketBeat Community Rating for Deciphera Pharmaceuticals (NASDAQ DCPH)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  261 (Vote Outperform)
Underperform Votes:  257 (Vote Underperform)
Total Votes:  518
MarketBeat's community ratings are surveys of what our community members think about Deciphera Pharmaceuticals and other stocks. Vote "Outperform" if you believe DCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel